#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Evolutionary Trajectories of Beta-Lactamase CTX-M-1 Cluster Enzymes: Predicting Antibiotic Resistance


Extended-spectrum beta-lactamases (ESBL) constitute a key antibiotic-resistance mechanism affecting Gram-negative bacteria, and also an excellent model for studying evolution in real time. A shift in the epidemiology of ESBLs is being observed, which is characterized by the explosive diversification and increase in frequency of the CTX-M-type β-lactamases in different settings. This provides a unique opportunity for studying a protein evolutionary radiation by the sequential acquisition of specific mutations enhancing protein efficiency and fitness concomitantly. The existence of driver antibiotic molecules favoring protein divergence has been investigated by combining evolutionary analyses and experimental site-specific mutagenesis. Phylogenetic reconstruction with all the CTX-M variants described so far provided a hypothetical evolutionary scenario showing at least three diversification events. CTX-M-3 was likely the enzyme at the origin of the diversification in the CTX-M-1 cluster, which was coincident with positive selection acting on several amino acid positions. Sixty-three CTX-M-3 derivatives containing all combinations of mutations under positively selected positions were constructed, and their phenotypic efficiency was evaluated. The CTX-M-3 diversification process can only be explained in a complex selective landscape with at least two antibiotics (cefotaxime and ceftazidime), indicating the need to invoke mixtures of selective drivers in order to understand the final evolutionary outcome. Under this hypothesis, we found congruent results between the in silico and in vitro analyses of evolutionary trajectories. Three pathways driving the diversification of CTX-M-3 towards the most complex and efficient variants were identified. Whereas the P167S pathway has limited possibilities of further diversification, the D240G route shows a robust diversification network. In the third route, drift may have played a role in the early stages of CTX-M-3 evolution. Antimicrobial agents should not be considered only as selectors for efficient mechanisms of resistance but also as diversifying agents of the evolutionary trajectories. Different trajectories were identified using a combination of phylogenetic reconstructions and directed mutagenesis analyses, indicating that such an approach might be useful to fulfill the desirable goal of predicting evolutionary trajectories in antimicrobial resistance.


Vyšlo v časopise: Evolutionary Trajectories of Beta-Lactamase CTX-M-1 Cluster Enzymes: Predicting Antibiotic Resistance. PLoS Pathog 6(1): e32767. doi:10.1371/journal.ppat.1000735
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000735

Souhrn

Extended-spectrum beta-lactamases (ESBL) constitute a key antibiotic-resistance mechanism affecting Gram-negative bacteria, and also an excellent model for studying evolution in real time. A shift in the epidemiology of ESBLs is being observed, which is characterized by the explosive diversification and increase in frequency of the CTX-M-type β-lactamases in different settings. This provides a unique opportunity for studying a protein evolutionary radiation by the sequential acquisition of specific mutations enhancing protein efficiency and fitness concomitantly. The existence of driver antibiotic molecules favoring protein divergence has been investigated by combining evolutionary analyses and experimental site-specific mutagenesis. Phylogenetic reconstruction with all the CTX-M variants described so far provided a hypothetical evolutionary scenario showing at least three diversification events. CTX-M-3 was likely the enzyme at the origin of the diversification in the CTX-M-1 cluster, which was coincident with positive selection acting on several amino acid positions. Sixty-three CTX-M-3 derivatives containing all combinations of mutations under positively selected positions were constructed, and their phenotypic efficiency was evaluated. The CTX-M-3 diversification process can only be explained in a complex selective landscape with at least two antibiotics (cefotaxime and ceftazidime), indicating the need to invoke mixtures of selective drivers in order to understand the final evolutionary outcome. Under this hypothesis, we found congruent results between the in silico and in vitro analyses of evolutionary trajectories. Three pathways driving the diversification of CTX-M-3 towards the most complex and efficient variants were identified. Whereas the P167S pathway has limited possibilities of further diversification, the D240G route shows a robust diversification network. In the third route, drift may have played a role in the early stages of CTX-M-3 evolution. Antimicrobial agents should not be considered only as selectors for efficient mechanisms of resistance but also as diversifying agents of the evolutionary trajectories. Different trajectories were identified using a combination of phylogenetic reconstructions and directed mutagenesis analyses, indicating that such an approach might be useful to fulfill the desirable goal of predicting evolutionary trajectories in antimicrobial resistance.


Zdroje

1. CantonR

CoqueTM

2006 The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 9 466 475

2. PitoutJD

LauplandKB

2008 Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8 159 166

3. ValverdeA

CoqueTM

Sanchez-MorenoMP

RollanA

BaqueroF

2004 Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 42 4769 4775

4. PetrosinoJ

CantuCIII

PalzkillT

1998 Beta-Lactamases: protein evolution in real time. Trends Microbiol 6 323 327

5. GniadkowskiM

2008 Evolution of extended-spectrum beta-lactamases by mutation. Clin Microbiol Infect 14 Suppl 1 11 32

6. DecousserJW

PoirelL

NordmannP

2001 Characterization of a chromosomally encoded extended-spectrum class A beta-lactamase from Kluyvera cryocrescens. Antimicrob Agents Chemother 45 3595 3598

7. HumeniukC

ArletG

GautierV

GrimontP

LabiaR

2002 Beta-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother 46 3045 3049

8. PoirelL

KampferP

NordmannP

2002 Chromosome-encoded Ambler class A beta-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum beta-lactamases. Antimicrob Agents Chemother 46 4038 4040

9. RodriguezMM

PowerP

RadiceM

VayC

FamigliettiA

2004 Chromosome-encoded CTX-M-3 from Kluyvera ascorbata: a possible origin of plasmid-borne CTX-M-1-derived cefotaximases. Antimicrob Agents Chemother 48 4895 4897

10. BarlowM

ReikRA

JacobsSD

MedinaM

MeyerMP

2008 High rate of mobilization for blaCTX-MS. Emerging Infectious Diseases 14 423 428

11. PoirelL

NaasT

NordmannP

2008 Genetic support of extended-spectrum beta-lactamases. Clin Microbiol Infect 14 Suppl 1 75 81

12. NovaisA

CantonR

ValverdeA

MachadoE

GalanJC

2006 Dissemination and persistence of blaCTX-M-9 are linked to class 1 integrons containing CR1 associated with defective transposon derivatives from Tn402 located in early antibiotic resistance plasmids of IncHI2, IncP1-alpha, and IncFI groups. Antimicrob Agents Chemother 50 2741 2750

13. CoqueTM

NovaisA

CarattoliA

PoirelL

PitoutJ

2008 Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 14 195 200

14. Nicolas-ChanoineMH

BlancoJ

Leflon-GuiboutV

DemartyR

AlonsoMP

2008 Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 61 273 281

15. CoqueTM

BaqueroF

CantonR

2008 Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 13 pii 19044

16. StepanovaMN

PimkinM

NikulinAA

KozyrevaVK

AgapovaED

2008 Convergent in vivo and in vitro selection of ceftazidime resistance mutations at position 167 of CTX-M-3 beta-lactamase in hypermutable Escherichia coli strains. Antimicrob Agents Chemother 52 1297 1301

17. CavacoLM

AbatihE

AarestrupFM

GuardabassiL

2008 Selection and persistence of CTX-M-producing Escherichia coli in the intestinal flora of pigs treated with amoxicillin, ceftiofur, or cefquinome. Antimicrob Agents Chemother 52 3612 3616

18. BonnetR

2004 Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48 1 14

19. BauernfeindA

GrimmH

SchweighartS

1990 A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 18 294 298

20. RossoliniGM

MantengoliE

2008 Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 14 Suppl 6 2 8

21. PoirelL

GniadkowskiM

NordmannP

2002 Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother 50 1031 1034

22. CartelleM

del MarTM

MolinaF

MoureR

VillanuevaR

2004 High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob Agents Chemother 48 2308 2313

23. NovaisA

CantonR

CoqueTM

MoyaA

BaqueroF

2008 Mutational events in ESBL-cefotaximases of the CTX-M-1 cluster involved in ceftazidime resistance. Antimicrob Agents Chemother 52 2377 82

24. BösF

PleissJ

2008 Conserved water molecules stabilize the Omega-loop in class A beta-lactamases. Antimicrob Agents Chemother 52 1072 1079

25. DelmasJ

ChenY

PratiF

RobinF

ShoichetBK

2008 Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. J Mol Biol 375 192 201

26. PoelwijkFJ

KivietDJ

WeinreichDM

TansSJ

2007 Empirical fitness landscapes reveal accessible evolutionary paths. Nature 445 383 386

27. WeinreichDM

DelaneyNF

DePristoMA

HartlDL

2006 Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312 111 114

28. OrenciaMC

YoonJS

NessJE

StemmerWP

StevensRC

2001 Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat Struct Biol 8 238 242

29. MartinezJL

BaqueroF

AnderssonDI

2007 Predicting antibiotic resistance. Nat Rev Micro 5 958 965

30. NovaisA

ComasI

CantonR

CoqueTM

BaqueroF

2008 Evolutionary trajectories among extended β-lactamase enzymes belonging to the CTX-M-1 cluster. 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona (Spain), April 2008

31. TianSF

ChenBY

ChuYZ

WangS

2008 Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 54 781 785

32. NaganoY

NaganoN

WachinoJ

IshikawaK

ArakawaY

2009 Novel chimeric β-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime. Antimicrob Agents Chemother 53 69 74

33. PoirelL

NaasT

LeTI

KarimA

BingenE

2001 CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop. Antimicrob Agents Chemother 45 3355 3361

34. Maynard SmithJ

1970 Natural selection and the concept of protein space. Nature 225 563 564

35. BaqueroF

BlazquezJ

1997 Evolution of antibiotic resistance. Trends Ecol Evol 12 482 487

36. WilkinsAS

1996 Antibiotic resistance: origins, evolution and spread. Ciba Foundation Symposium, 16-18 July 1996, London. Bioessays 18 847 848

37. NegriMC

LipsitchM

BlazquezJ

LevinBR

BaqueroF

2000 Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. Antimicrob Agents Chemother 44 2485 2491

38. BlazquezJ

MorosiniMI

NegriMC

BaqueroF

2000 Selection of naturally occurring extended-spectrum TEM beta-lactamase variants by fluctuating beta-lactam pressure. Antimicrob Agents Chemother 44 2182 2184

39. WagnerA

2008 Robustness and evolvability: a paradox resolved. Proc R Soc B 275 91 100

40. LenskiRE

BarrickJE

OfriaC

2006 Balancing robustness and evolvability. PLoS Biol 4 e428 doi:10.1371/journal.pbio.0040428

41. BershteinS

GoldinK

TawfikDS

2008 Intense neutral drifts yield robust and evolvable consensus proteins. J Mol Biol 379 1029 1044

42. CharlesworthB

2009 Fundamental concepts in genetics: Effective population size and patterns of molecular evolution and variation. Nat Rev Genet 10 195 205

43. BaqueroMR

NilssonAI

del Carmen TurrientesM

SandvangD

GalanJC

2004 Polymorphic mutation frequencies in Escherichia coli: Emergence of weak mutators in clinical isolates. J Bacteriol 186 5538 5542

44. EllingtonMJ

LivermoreDM

PittTL

HallLM

WoodfordN

2006 Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance. J Antimicrob Chemother 58 848 852

45. BorgMA

ZarbP

FerechM

GoossensH

2008 Antibiotic consumption in southern and eastern Mediterranean hospitals: results from the ARMed project. J Antimicrob Chemother 62 830 836

46. ThompsonJD

HigginsDG

GibsonTJ

1994 CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucl Acids Res 22 4673 4680

47. RonquistF

HuelsenbeckJP

2003 MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics 19 1572 1574

48. GuindonS

GascuelO

2003 A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Systematic Biology 52 696 704

49. PosadaD

CrandallKA

1998 Modeltest: testing the model of DNA substitution. Bioinformatics 14 917 918

50. AnisimovaM

GascuelO

2006 Approximate likelihood-ratio test for branches: a fast, accurate, and powerful alternative. Systematic Biology 55 539 522

51. SaitouN

NeiM

1987 The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol Biol Evol 4 406 425

52. KumarS

NeiM

DudleyJ

TamuraK

2008 MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 9 299 306

53. BandeltHJ

ForsterP

RohlA

1999 Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 16 37 48

54. AmblerRP

CoulsonAF

FrereJM

GhuysenJM

JorisB

1991 A standard numbering scheme for the class A beta-lactamases. Biochem J 276 (Pt 1) 269 270

55. MaddisonWP

MaddisonDR

2009 Mesquite: a modular system for evolutionary analysis, version 2.6 [computer program]

56. YangZ

2007 PAML 4: Phylogenetic Analysis by Maximum Likelihood. Mol Biol Evol 24 1586 1591

57. YangZ

NielsenR

GoldmanN

PedersenAMK

2000 Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics 155 431 449

58. YangZ

WongWSW

NielsenR

2005 Bayes empirical Bayes inference of amino acid sites under positive selection. Mol Biol Evol 22 1107 1118

59. ZhangJ

NielsenR

YangZ

2005 Evaluation of an improved branch-site likelihood method for detecting positive selection at the molecular level. Mol Biol Evol 22 2472 2479

60. SprattBG

HedgePJ

te HeesenS

EdelmanA

Broome-SmithJK

1986 Kanamycin-resistant vectors that are analogues of plasmids pUC8, pUC9, pEMBL8 and pEMBL9. Gene 41 337 342

61. CondonC

WeinerJH

1988 Fumarate reductase of Escherichia coli: an investigation of function and assembly using in vivo complementation. Mol Microbiol 2 43 52

62. GillespieJH

1984 Molecular evolution over the mutational landscape. Evolution 38 1116 1129

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2010 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Aktuální možnosti diagnostiky a léčby litiáz
nový kurz
Autori: MUDr. Tomáš Ürge, PhD.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#